Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- STATISTICS
March 20, 2006
- SEMINAR
March 20, 2006
- Major Products, Major Firms Hit Hard: NHI Price Revision
March 20, 2006
- HUMAN RESOURCES
March 20, 2006
- Proposed Policy on Return of Goods Approved by Ryukaikon
March 13, 2006
- Korosho Wants to See All Original Brands Available at the Same Strengths
March 13, 2006
- REGULATORY NEWS IN BRIEF
March 13, 2006
- Hayashibara to Develop Alzheimer's Disease Vaccine
March 13, 2006
- Explanatory Meeting on JapicCTI
March 13, 2006
- ＜JCROA Seminar＞Collaborative Int'l Trials Remain Risky: Dr Iwasaki of EFPIA
March 13, 2006
- GENERICS NEWS IN BRIEF
March 13, 2006
- R&D NEWS IN BRIEF
March 13, 2006
- Eisai Aims at \1 Tril. Sales in FY2011
March 13, 2006
- SELF-MEDICATION NEWS IN BRIEF
March 13, 2006
- Mr Iwasaki to Implement Reform through Dialogues with Employees: Pfizer
March 13, 2006
- OPINION
March 13, 2006
- Takeda Promoting Basen OD Tables to Win Market Competition
March 13, 2006
- JPA Holds 100th Assembly of House of Delegates
March 13, 2006
- Norvasc Was Most-prescribed Drug in 2005: IMS Japan
March 13, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 13, 2006
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…